Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Hovacre, regarding the statement below, this trial involves ADXS PSA combined with Merck PD1 compared to ADXS PSA monotherapy. Do you know if separately Merck has any comparable data on its PD1 prostate monotherapy? If for example, Merck PD1 produced declines closer to our mono therapy 15.4% that would mean the combo is truly superior versus if Merck mono therapy alone produced closer to 40.5% which would mean our vaccine is not adding much to Merck's construct alone.

"The percentage of patients with PSA declines from baseline in the combination therapy arm was 40.5%, and 15.4% in the monotherapy arm."